Vaxxas is actively seeking partnerships with vaccine companies that have an interest in benefitting from the Nanopatch™ technology. We seek to work in partnership to optimise our delivery technology for the vaccines of interest and help our partners to deliver a cost effective, differentiated, high performance and safe product in the shortest timeframe possible. We believe that Nanopatch™ can:
- Enhance the therapeutic and market potential of existing vaccines, and
- Provide unprecedented immunogenic response to enable new, next generation vaccines.
Professor Kendall at The University of Queensland (www.aibn.uq.edu.au/mark-kendall) has collaborated with research institutes worldwide including Oxford University, University of Washington, University of Melbourne and is also in close contact with PATH and the WHO.